References
- Silman A., Hochberg M. C. Epidemiology of rheumatic diseases. Oxford University Press, Oxford 1993
- Fex E., Larsson B‐M., Nived K., Eberhardt K. Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1997; 25: 44–50
- Hallert E., Husberg M., Jonsson D., Skough T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 2006; 45: 325–31
- Stone C. E. The lifetime economic cost of rheumatoid arthritis. J Rheumatol 1984; 11: 819–27
- McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781–90
- Kobelt G., Eberhardt K., Jonsson L., Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56
- Söderlin M. K., Kautiainen H., Jonsson D., Skogh T., Leirisalo‐Repo M. The costs of early inflammatory joint disease: a population‐based study in southern Sweden. Scand J Rheumatol 2003; 32: 216–24
- Michaud K., Messer J., Choi H. K., Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 2750–62
- Kobelt G., Lindgren P., Singh A., Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64: 1174–9
- Jacobsson L., Lindroth Y., Marsal L., Tejler L. [The Malmo model for private and public rheumatological outpatient care. Cooperation makes it possible to introduce disease modifying treatment quickly] in Swedish. Lakartidningen 2001; 98: 4710–16
- Kobelt G., Lindgren P., Lindroth Y., Jacobsson L. T., Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005; 44: 1169–75
- Kobelt G., Eberhardt K., Geborek P. TNF‐inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow‐up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4–10
- Jonsson B., Kaarela K., Kobelt G. Economic consequences of the progression of rheumatoid arthritis. A Markov model. Stockholm School of Economics, Stockholm 1997
- Jonsson D., Husberg G. Socioeconomic costs of rheumatic diseases: implications for technology assessment. Int J Technol Assess Health Care 2000; 16: 193–200
- Kobelt G., Jonsson L., Lindgren P., Young A., Eberhardt K. Modelling the progression of rheumatoid arthritis. A two‐country model to estimate costs and consequences of RA. Arthritis Rheum 2002; 46: 2310–19